>
Floating Energy Assets Explained
What if Iran's next move against Washington is not a missile launch, but a convoy of oil tankers
Artificial Intelligence Could Transform Bank Runs From Hours-Long Crises...
Dubai Just Finished the World's First Permanent Air Taxi Route: Airport to the Marina in Under 1
Doroni Aerospace Raises More than $60m for H1?X Development
After 13 Years Battling Cancer, a 61-Year-Old Brazilian Man Achieved Complete Remission...
Extraterrestrial habitats may rise via Legos of laser-fused moon dust
Battery-only 19-seater puts China in the electric airliner race
Dream Chaser space plane gets landing approval for debut mission in 2027
SpaceX Just Caught Starship on Its FIRST Attempt!
Solid-State Cells Can Make The U.S. Competitive In Batteries Again: CEO
Jetson ONE personal eVTOL pod is about to go full sky patrol
America's INSANE BREAKTHROUGH Could Replace Septic Tanks Forever

It's opened the door to developing a drug to treat the condition for which existing painkillers do little.
Diabetes, chemotherapy drugs, multiple sclerosis, injuries and amputations have all been associated with neuropathic pain, usually caused by damage to nerves in various body tissues, including the skin, muscles and joints. Mechanical hypersensitivity – or mechanical allodynia – is a major symptom of neuropathic pain, where innocuous stimuli like light touch cause severe pain.
Many available pain medications aren't effective in reducing this often-debilitating type of chronic pain. However, researchers at the University of Texas at Austin (UT Austin), in collaboration with UT Dallas and the University of Miami, may have advanced the treatment of neuropathic pain by discovering a molecule that reduces mechanical hypersensitivity in mice.
"We found it to be an effective painkiller, and the effects were rather long-lived," said Stephen Martin, a co-corresponding author of the study. "When we tested it on different models, diabetic neuropathy and chemotherapy-induced neuropathy, for example, we found this compound has an incredible beneficial effect."
The compound is FEM-1689, which binds to the sigma 2 receptor (σ2R), which was identified in 2017 as transmembrane protein 97 (TMEM97). The researchers had previously found that several small molecules that bind selectively to σ2R/TMEM97 produce strong and long-lasting anti-neuropathic pain effects in mice. FEM-1689, one such small molecule, was found to have improved selectivity for σ2R/TMEM97.